Ryvu Therapeutics Income Statement

Financials in millions PLN. Fiscal year is January - December.

Millions PLN. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	87.7	101.96	67.3	68.44	35.41
Other Revenue	-	-	-	-	0
Revenue	87.7	101.96	67.3	68.44	35.41
Revenue Growth (YoY)	-13.98%	51.51%	-1.67%	93.25%	-4.16%
Cost of Revenue	14.8	19.58	17.55	17.41	13.73
Gross Profit	72.9	82.38	49.74	51.03	21.69
Selling, General & Admin	152.28	183.59	123.46	84.55	64.35
Other Operating Expenses	8.4	10.27	12.68	23.08	23.66
Operating Expenses	170.11	204.35	147.12	120.53	100.57
Operating Income	-97.21	-121.97	-97.38	-69.49	-78.89
Interest Expense	-8.8	-3.81	-0.1	-1.09	-0.44
Interest & Investment Income	5.09	9.13	13.83	1.15	0.06
Currency Exchange Gain (Loss)	0.47	-1.21	-4.9	-0.83	0.02
Other Non Operating Income (Expenses)	9.71	6.85	-0	0	0
EBT Excluding Unusual Items	-90.74	-111.01	-88.54	-70.27	-79.25
Gain (Loss) on Sale of Investments	-10.4	-0.13	-3.57	-8.93	0.29
Pretax Income	-101.14	-111.14	-92.11	-79.2	-78.96
Income Tax Expense	0.09	0.3	-	4.59	0.12
Earnings From Continuing Operations	-101.23	-111.44	-92.11	-83.78	-79.08
Net Income to Company	-101.23	-111.44	-92.11	-83.78	-79.08
Net Income	-101.23	-111.44	-92.11	-83.78	-79.08
Net Income to Common	-101.23	-111.44	-92.11	-83.78	-79.08
Shares Outstanding (Basic)	23	23	23	18	18
Shares Outstanding (Diluted)	23	23	23	18	18
Shares Change (YoY)	-	0.97%	24.75%	-	9.48%
EPS (Basic)	-4.38	-4.82	-4.02	-4.56	-4.31
EPS (Diluted)	-4.38	-4.82	-4.02	-4.56	-4.31
Free Cash Flow	-121.57	-135.38	-93.13	15.07	-70.87
Free Cash Flow Per Share	-5.26	-5.86	-4.07	0.82	-3.86
Gross Margin	83.12%	80.80%	73.91%	74.57%	61.24%
Operating Margin	-110.84%	-119.63%	-144.70%	-101.54%	-222.76%
Profit Margin	-115.42%	-109.29%	-136.88%	-122.42%	-223.30%
Free Cash Flow Margin	-138.62%	-132.78%	-138.39%	22.01%	-200.12%
EBITDA	-87.99	-111.76	-87.32	-58.16	-67.94
EBITDA Margin	-100.33%	-109.61%	-129.76%	-84.99%	-191.85%
D&A For EBITDA	9.22	10.22	10.05	11.33	10.95
EBIT	-97.21	-121.97	-97.38	-69.49	-78.89
EBIT Margin	-110.84%	-119.63%	-144.70%	-101.54%	-222.76%
Revenue as Reported	87.7	101.96	67.3	68.44	35.41

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.